Depression

Three Infusions, Eleven Days: What the Bio-K Study Found in Real-World Clinics

Clinical trials often exclude the patients who most need help: people with suicidal thoughts, with bipolar disorder, or with many failed treatments behind them. The Bio-K study set out to see how ketamine performs in exactly those patients, in ordinary clinics.

The study

Bio-K was led by Dr Sagar Parikh at the University of Michigan, with Johns Hopkins University, Mayo Clinic and Pine Rest Christian Mental Health Services. It was published in the Journal of Affective Disorders in 2024.

It enrolled 74 people with severe depression or bipolar disorder at four clinics in Michigan, Maryland and Minnesota. All had failed at least two medication trials or a course of ECT. Each received three intravenous ketamine infusions over 11 days. The study was open-label, meaning everyone knew they were getting ketamine.

The results

  • Average depression score fell from 28 before treatment to 11 one day after the third infusion.
  • Remission: 52% of participants.
  • Response, including those in remission: 67%.
  • About a third did not respond.

Suicidal thoughts

More than 80% of participants had suicidal thoughts serious enough to have excluded them from many depression studies. Among those who had frequent suicidal thoughts before treatment, half experienced a dramatic drop.

Two practical findings

  • Early response matters. Two-thirds of people who responded after the first infusion went on to reach remission. People who showed no measurable response after two infusions were unlikely to respond to a third. That gives patients and clinicians an early signal for deciding whether to continue.
  • Infusion length did not matter. Some participants received ketamine over the standard 40 minutes and others slowly over 100 minutes. Results were the same.

The caveats

Bio-K had no placebo group, so some of the improvement may reflect expectation. That concern is real: the later KARMA-Dep 2 trial, which used an active comparison, found no added benefit from ketamine in hospitalised patients. Bio-K also measured results one day after the last infusion, so it does not show how long the improvement lasts.

Open questions

The researchers are studying whether blood markers can predict who will benefit, and a larger randomized study funded by the Patient-Centered Outcomes Research Institute is planned to compare IV ketamine with esketamine (“the S-form of ketamine, sold as Spravato”) nasal spray directly. Insurance coverage also remains inconsistent, because IV ketamine is not FDA-approved for depression.

Sources and further reading

  1. Ketamine’s promise for severe depression grows, but major questions remain (ScienceDaily, February 8, 2024)
  2. Intravenous Ketamine for Treatment-Resistant Depression: study listing (Mayo Clinic)

This article is for education only and is not medical advice. Talk with a licensed provider about whether any treatment is right for you.

Free ConsultationSchedule
Online
Talk to ProviderCall us